RESUMO
OBJECTIVE: COVID-19 spread worldwide, causing severe morbidity and mortality and this process still continues. The aim of this study to investigate the prognostic value of right ventricular (RV) strain in patients with COVID-19. METHODS: Consecutive adult patients admitted to the emergency room for COVID-19 between 1 and 30 April were included in this study. ECG was performed on hospital admission and was evaluated as blind. RV strain was defined as in the presence of one or more of the following ECG findings: complete or incomplete right ventricular branch block (RBBB), negative T wave in V1-V4 and presence of S1Q3T3. The main outcome measure was death during hospitalization. The relationship of variables to the main outcome was evaluated by multivariable Cox regression analysis. RESULTS: A total of 324 patients with COVID-19 were included in the study; majority of patients were male (187, 58%) and mean age was 64.2 ± 14.1. Ninety-five patients (29%) had right ventricular strain according to ECG and 66 patients (20%) had died. After a multivariable survival analysis, presence of RV strain on ECG (OR: 4.385, 95%CI: 2.226-8.638, p < 0.001), high-sensitivity troponin I (hs-TnI), d-dimer and age were independent predictors of mortality. CONCLUSION: Presence of right ventricular strain pattern on ECG is associated with in hospital mortality in patients with COVID-19.
Assuntos
COVID-19/mortalidade , COVID-19/fisiopatologia , Eletrocardiografia/métodos , Disfunção Ventricular Direita/fisiopatologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Arritmias Cardíacas/fisiopatologia , Feminino , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Mortalidade Hospitalar , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Troponina I/análise , Turquia/epidemiologiaRESUMO
INTRODUCTION: Although patients with tombstoning ST-segment elevation (Tomb-ST) usually have poor in-hospital and short-term survival rates, no studies have examined the long-term clinical outcomes and prognosis of ST-segment elevation myocardial infarction (STEMI) patients who have this electrocardiographic pattern. Therefore, we aimed to evaluate the long-term clinical events and mortality of such patients in this study. METHODS: In this retrospective analysis, we included 335 consecutive patients who were diagnosed with acute anterior wall-STEMI from January 2015 to June 2018. The criteria for the definition of Tomb-ST were accepted as provided in a previous study. Endpoints of the study were the incidence of significant in-hospital and long-term major adverse clinical events (MACE) including the composite of total death, myocardial reinfarction, and hospitalizations due to heart failure. RESULTS: Patients who presented with Tomb-ST had significantly higher in-hospital and long-term mortality (10% [n = 12 patients] vs. 2.3% [n = 5 patients]; p < 0.001and 6.5% [n = 7 patients] vs. 1.9% [n = 4 patients]; p = .04, respectively). In a multivariate traditional and penalized Cox proportional hazard regression analysis, this type of electrocardiographic pattern was found as independent predictor of long-term MACE (Odds ratio [OR]: 3.82, 95% confidence interval [CI]: 1.91-7.63, p < .001 and OR: 4.36, 95% CI: 1.97-9.66, p < .001, respectively). CONCLUSION: In the present study, we observed that the presence of Tomb-ST might be an independent predictor of long-term MACE in STEMI patients. To the best of our knowledge, this is the first study to evaluate the long-term MACE of such patients.
Assuntos
Eletrocardiografia , Infarto do Miocárdio com Supradesnível do Segmento ST/fisiopatologia , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Recidiva , Estudos Retrospectivos , Fatores de Risco , Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade , Análise de SobrevidaRESUMO
INTRODUCTION: The primary goal in the management of acute ST segment elevation myocardial infarction (STEMI) is to open the occluded artery at an early stage. The development of no-reflow is multifactorial, and the etiology is not fully understood. There is accumulating evidence that anemia is related to a series of severe complications in cardiovascular disease (CVD) such as thromboembolic events, bleeding complications, uncontrolled hypertension, and inflammation characterized by elevated levels of inflammatory cytokines. AIM: We investigated the relationship between hemoglobin level and the no-reflow of infarct-related artery (IRA) in patients with STEMI undergoing primary percutaneous coronary intervention (PPCI). MATERIAL AND METHODS: A total of 3804 patients with acute STEMI who underwent PPCI were enrolled. The patients were divided into two groups according to thrombolysis in myocardial infarction (TIMI) flow grades after PPCI. Hematological parameters were measured on admission. Univariate and multivariate logistic regression analyses were conducted to assess the association between hemoglobin level and no-reflow. RESULTS: In the current study, 471 (12.4%) patients presented with no-reflow after PPCI. The patients in the no-reflow group had a significantly lower hemoglobin level (12.1 ±1.9 g/dl vs. 13.8 ±1.8 g/dl, p < 0.001). The multivariate logistic regression models revealed that hemoglobin level (OR = 0.564, 95% CI: 0.526-0.605; p < 0.001) was an independent predictor of development of no-reflow. The cutoff value for hemoglobin level was 11.5 g/dl with sensitivity of 83.0% and specificity of 80.0% (AUC = 0.844, 95% CI: 0.821-0.867; p < 0.001). CONCLUSIONS: Our results suggest that hemoglobin level showed a moderate diagnostic performance regarding the prediction of no-reflow in patients with STEMI undergoing PPCI.
RESUMO
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease characterized by ventricular hypertrophy, myocardial fibrosis, and impaired ventricular relaxation. The exact mechanisms by which fibrosis is caused remain unknown. HYPOTHESIS: Circulating TGF-ß is related to poor prognosis in HCM. METHODS: We compared TGF-ß levels of 49 HCM patients with those of 40 non-HCM patients. We followed the patients with HCM for 18 months and divided them into 2 groups: low TGF-ß (≤ 4877 pg/mL) and high TGF-ß (> 4877 pg/mL). We compared the 2 groups in terms of brain natriuretic peptide (BNP), echocardiographic parameters, and clinical outcomes including myocardial infarction, arrhythmias, implantable cardioverter-defibrillator implantation, hospitalization, New York Heart Association (NYHA) class, acute heart failure, and mortality. RESULTS: The HCM patients had higher TGF-ß levels than those in the control group (P = 0.005). In the follow-up, those in the high TGF-ß group had higher BNP levels, larger left-atrial size, thicker interventricular septum, NYHA class, more hospitalizations, and a greater number of clinical adverse events (P < 0.001, P = 0.01, P < 0.001, P = 0.002, P < 0.001 and P = 0.003, respectively). TGF-ß level of > 4877 pg/mL can predict adverse events with a specificity of 75% and a sensitivity of 72% (P = 0.014). In multivariate regression analysis, TGF-ß, BNP, and interventricular septum thickness were significantly associated with adverse events (P = 0.028, P = 0.030, and P = 0.034, respectively). CONCLUSIONS: The TGF-ß level is higher in HCM patients and associated with a poor prognosis in HCM.
Assuntos
Cardiomiopatia Hipertrófica/sangue , Fator de Crescimento Transformador beta1/sangue , Adulto , Cardiomiopatia Hipertrófica/diagnóstico por imagem , Cardiomiopatia Hipertrófica/mortalidade , Ensaio de Imunoadsorção Enzimática , Feminino , Hospitalização , Humanos , Masculino , Pessoa de Meia-Idade , Peptídeo Natriurético Encefálico/sangue , Prognóstico , Ultrassonografia , Adulto JovemAssuntos
Choque Cardiogênico/diagnóstico , Disfunção Ventricular Esquerda/diagnóstico , Idoso , Dor no Peito/etiologia , Diagnóstico Diferencial , Eletrocardiografia , Coração Auxiliar , Humanos , Balão Intra-Aórtico , Masculino , Intervenção Coronária Percutânea/métodos , Choque Cardiogênico/complicações , Choque Cardiogênico/terapia , Disfunção Ventricular Esquerda/complicações , Disfunção Ventricular Esquerda/terapia , Adulto JovemRESUMO
AIM: P wave dispersion (PWD) has been shown to be a noninvasive predictor for the development of atrial ï¬brillation (AF). Atorvastatin is a 3 hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor that lowers blood cholesterol levels. The beneficial effect of atorvastatin on atrial arrhythmias is controversial. Aim of this study was to investigate the effect of atorvastatin treatment on PWD in hyperlipidemic patients. METHODS: Seventy-nine newly diagnosed hyperlipidemic patients and 30 normolipidemic healthy subjects were enrolled in this study. All hyperlipidemic patients received atorvastatin 20-40 mg/ day according to their cholesterol levels and hypolipidemic diet treatment. Twelve-lead surface electrocardiogram (ECG) were recorded from hyperlipidemic patients before and after 6-months of atorvastatin therapy and from control group at their first visit. The P-wave duration measurements were calculated from these surfaces of ECG. RESULTS: When pretreatment PWD, P maximum and P minimum values were compared with post-treatment values, a statistically significant decrease was found after 6 months (p less than 0.001, p=0.012 and p=0.007, respectively). CONCLUSION: Atorvastatin lowered PWD significantly, so this finding may be important in the prevention of AF in hyperlipidemic patients.